The FDA accepted for review Eisai subsidiary Morphotek's investigational new drug application for MORAb-202, which combines farletuzumab with eribulin to treat patients with solid tumors that express folate receptor alpha.
Morphotek's IND for tumor drug accepted for FDA review
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.